AI-guided redesign of protein alphabet in bacteria could unlock new ways to build synthetic organisms.

Nvidia is the current hardware leader, but Broadcom, AMD, and Alphabet are chipping away at its lead. Alphabet is a leader in AI software and has introduced a hardware competitor to Nvidia's GPU.

Alphabet's life sciences business Verily is restructuring and raising money as a new corporate entity. Verily announced that with its $300 million investment round, it will change from an LLC to a ...

The Angels reassigned Madrigal to minor-league camp Saturday. Madrigal inked a minor-league deal with an invitation to spring training back in January, but he appears set to open the season in ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH), the pressure is on for Madrigal Pharmaceuticals’ Rezdiffra ...

Madrigal Pharmaceuticals (MDGL) lost ~8% in the premarket on Thursday after the maker of the liver disease therapy, Rezdiffra, posted a mixed financial report for Q4 2025, indicating a ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. Just weeks after betting $50 million on a DGAT2i ...

Alphabet's latest stock surge brought its valuation past $4 trillion on Monday. Shares of the Google parent soared 65% last year amid the broader AI rally. It marks the first time its stock has ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra. Madrigal’s thyroid hormone ...

Google parent company Alphabet saw its market capitalization surpass Apple's for the first time since 2019. Alphabet's market cap closed at $3.88 trillion on Wednesday, while Apple's market cap closed ...

When I last covered Madrigal Pharmaceuticals (MDGL) in February last year, I was reviewing the company's Q4 and full-year 2024 earnings. Rezdiffra, Madrigal's only commercial asset, the first drug ...